|Home | About | Journals | Submit | Contact Us | Français|
“Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis” by Kerlikowske et al. [J Natl Cancer Inst 2010;102(9): 627–637]. There was an error in Table 2 of this paper. The numbers of samples by tumor size were mistakenly switched between the rows for tumors larger than 10 mm and for tumors 10 mm or smaller. The first two rows of the table should have read as follows:
The eighth footnote in Table 6 was incomplete. It should have read:
** DCIS with margins of 1 millimeter or greater disease-free plus estrogen receptor (ER) positive and HER2/neu-oncoprotein (ERBB2) negative and Ki67-negative (ER+ERBB2-Ki67-) or estrogen receptor (ER) positive and HER2/neu-oncoprotein (ERBB2) negative and Ki67-positive (ER+ERBB2-Ki67+) or estrogen receptor (ER) positive and HER2/neu-oncoprotein (ERBB2) positive and Ki67-negative (ER+ERBB2+Ki67-).
Also, the corresponding author's e-mail address was incorrectly listed. It should have read: ude.fscu@ekswokilreK.alraK. The authors regret the errors.
|Factor‡||No subsequent tumor event*(N = 279) % (No.)||Invasive event (N = 114) % (No.)||Risk of invasive event HR (95% CI)||DCIS event (N = 109) % (No.)||Risk of DCIS event HR†(95% CI)|
|> 10 mm||30 (85)||39 (44)||1.2 (0.8 to 1.8)||41 (45)||1.4 (1.0 to 2.1)|
|≤ 10 mm||70 (194)||61 (70)||1.0 (referent)||59 (64)||1.0 (referent)|